Table 4 Acute exacerbation while on nintedanib medication within one year

(n = 111)

(n = 11)

(n = 100)

Age (years)

69 (66–74)

70 (66–75.3)

70 (66–75.8)

0.8279

Male, n (%)

80 (72.1)

11 (100)

69 (69)

0.0324

IPF/PF-ILD/SSc-ILD

59/35/17

7/4/0

52/31/17

0.3828

Smoking (pack-years)

40 (18.5–82.8)

40 (20–60)

40 (20–58.5)

0.7599

BMI (kg/m²)

22.9 (20.6–25.2)

23.4 (20.3–24.8)

22.7 (20.6–25.3)

0.9214

BSA (m²)

1.62 (1.51–1.72)

1.68 (1.60–1.72)

1.61 (1.50–1.72)

0.1582

Albumin

3.87 (3.59–4.10)

3.3 (3.27–3.76)

3.9 (3.7–4.1)

0.0030

 C-reactive protein (mg/dL)

0.28 (0.10–0.59)

0.56 (0.16–0.89)

0.24 (0.10–0.56)

0.0986

KL-6 (U/mL)

943 (633–1463)

1379 (946–1919)

908 (624–1361)

0.0552

White blood cell count (x10⁹/L)

7.400 (6.000–9.700)

8.400 (6.800–11.200)

7.200 (5.900–9.475)

0.0924

Monocyte count (x10⁹/L)

0.451 (0.352–0.600)

0.581 (0.296–0.694)

0.449 (0.358–0.580)

0.7612

mMRC score*

1.62 ± 1.05

2.63 ± 0.30

1.51 ± 0.10

0.0009

FVC

2.18 (1.61–2.86)

2.31 (1.59–2.69)

2.18 (1.60–2.88)

0.9517

%FVC

70.4 (57.1–87.4)

70.2 (47.1–77.4)

70.5 (59.2–87.7)

0.3137

%DLco

56.3 (44.8–73.7)

45.6 (37–55.8)

57.3 (46.6–74.7)

0.0667

Low pulmonary function, n (%)

27 (24.5)

5 (55.6)

22 (22)

0.0400

GAP stage*

2.61 ± 0.96

3.36 ± 0.28

2.53 ± 0.09

0.0052

Starting dosage 300 mg (%)

83 (74.8)

10 (90.1)

73 (73.0)

0.3137